Damora Therapeutics CFO Lori Firmani to depart May 1; Brian Burkavage appointed principal financial officer

Damora Therapeutics, Inc.

Effective May 1, 2026, Lori Firmani will cease serving as CFO of Damora Therapeutics.
Firmani receives lump-sum salary continuation, prorated bonus, $6K HSA, and full equity acceleration.
Brian Burkavage, current SVP Finance, appointed principal financial and accounting officer effective May 1.
Burkavage previously SVP Finance and CAO at IO Biotech; CPA with 11 years at Ernst & Young.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brian Burkavage

principal financial officer and principal accounting officer

DMRA · Damora Therapeutics, Inc.

Effective: 2026-05-01
Filed: May 4, 2026, 7:59 PM ET

the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.

Departed

Lori Firmani

Chief Financial Officer

DMRA · Damora Therapeutics, Inc.

Effective: 2026-05-01
Successor: Brian Burkavage
Filed: May 4, 2026, 7:59 PM ET

the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian Burkavage was appointed as principal financial officer and principal accounting officer at Damora Therapeutics, Inc..

Action: appointed
Role: principal financial officer and principal accounting officer

Exact text from the filing

the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Lori Firmani departed as Chief Financial Officer at Damora Therapeutics, Inc..

Action: would cease serving
Role: Chief Financial Officer

Exact text from the filing

the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.

View on SEC.gov

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-203913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.